Abstract
CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 33-38 |
| Number of pages | 6 |
| Journal | SENDROM |
| Volume | 16 |
| Issue number | 12 |
| State | Published - Dec 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Yeni bir biyolojik belirteç olarak C-reaktif protein. / Elgharib, Nader; Chi, David S.; Younis, Walid; Wehbe, Salim; Krishnaswamy, Guha.
In: SENDROM, Vol. 16, No. 12, 12.2004, p. 33-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Yeni bir biyolojik belirteç olarak C-reaktif protein
AU - Elgharib, Nader
AU - Chi, David S.
AU - Younis, Walid
AU - Wehbe, Salim
AU - Krishnaswamy, Guha
PY - 2004/12
Y1 - 2004/12
N2 - CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.
AB - CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.
UR - http://www.scopus.com/inward/record.url?scp=11844262716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11844262716&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:11844262716
VL - 16
SP - 33
EP - 38
JO - SENDROM
JF - SENDROM
SN - 1016-5134
IS - 12
ER -